# Kilroy Realty (KRC) investment thesis

By Clearthesis. Data as of July 1, 2026. Written July 1, 2026. Full page: https://www.clearthesis.ai/thesis/KRC?utm_source=ai_agent&utm_medium=markdown

Kilroy Realty is a high-end property owner on the West Coast that is trying to survive the decline of traditional office space by building specialized labs for biotech companies.

The question investors are asking: Kilroy Realty's stock has struggled as many of its West Coast offices sit empty. Can its new push into biotech labs save the business, or is the office market permanently broken?

## Summary

Kilroy owns premier real estate in tech hubs but is currently being drained by a record-high vacancy rate of 18.4%. The business stays in the "Watch" category until it proves it can fill its empty buildings without cutting rents.

## The thesis in brief

- Kilroy Realty is a West Coast landlord that owns high-end office and life science properties in tech hubs, bringing in $1.11 billion in revenue last year. It is currently managing a hard transition as vacancies have reached a high 18.4% across its core markets.
- The investment thesis on Kilroy Realty is that its pivot into life science labs is moving too slowly to offset the decay of its traditional office portfolio. While its premier locations provide a narrow moat, they are not enough to protect cash flow while nearly a fifth of its buildings sit empty.
- The main growth driver is the lease-up of its development pipeline, which focuses on new projects built specifically for biotech tenants in prime coastal spots. Success requires finding these tenants while high interest rates make its $5 billion debt load a heavy burden to carry.
- The biggest risk is a prolonged downturn in tech spending that leaves these buildings empty for years, because premium properties require high-paying tenants to be profitable. We avoid the stock because the business is weakening as vacancies sit at levels that are dangerous for any landlord.

- Kilroy Realty is a West Coast landlord pivoting $1.11 billion in revenue from offices to biotech labs.
- The turnaround is struggling as its vacancy rate has climbed to a dangerous 18.4%.
- Growth depends on finding lab tenants while carrying a heavy $5 billion debt load.
- We lean toward avoiding the stock because the business is weakening and the valuation is stretched.

## The business

- Stage: Mature

What does it do? Kilroy Realty is a mature real estate business that earns money by owning, developing, and leasing high-quality office and laboratory space to tech and life science companies. As a Real Estate Investment Trust (REIT), it buys or builds properties in concentrated West Coast clusters and signs long-term contracts with tenants who pay monthly rent and a share of operating costs. Its revenue flows directly from these lease agreements, which typically last several years and include annual rent increases. Customers keep paying because Kilroy’s buildings are in "trophy" locations with modern amenities that help companies attract top talent.

Where does revenue come from? The vast majority of Kilroy’s revenue comes from base rent and expense reimbursements from its portfolio of office and life science buildings. It manages over 13 million square feet of space across four main regions: San Francisco, Los Angeles, San Diego, and Seattle. While traditional office space is still the largest segment, the company is actively shifting its mix toward life science laboratories to capture more stable demand from the biotech industry.

Who are its customers? Kilroy Realty serves a concentrated group of large technology firms and growing life science companies that require specialized, premium workspaces. Its top tenants often include names like Adobe, Salesforce, and pharmaceutical giants, though its total portfolio occupancy ended 2025 at 81.6%. The company signed a record volume of new leases in the fourth quarter of 2025, but it is still working to fill the 18.4% of its space that remains vacant. It tracks its success through the "leased-to-economic occupancy" spread, which represents the rent it has signed but has not yet started collecting.

What gives it staying power? Kilroy’s staying power comes from owning some of the most technologically advanced and environmentally sustainable buildings in land-constrained coastal markets. These "Class A" properties are difficult for competitors to build from scratch because of high costs and strict local zoning. However, this advantage is currently under pressure as remote work reduces the overall need for office space.

Where is it headed? Kilroy is making a major strategic bet on the life science sector by acquiring and developing lab-ready buildings in San Diego’s Torrey Pines cluster. Management recently bought the Nautilus campus for $192 million to expand its footprint in one of the few markets where tenant demand remains strong. If this shift works, Kilroy will become less dependent on the volatile tech office market and more tied to the steady growth of biotech research.

## Financial performance

The most important trend is that Kilroy is seeing a divergence between its steady revenue and a sharp decline in its actual earnings power. While annual revenue held steady at $1.11 billion in 2025, GAAP earnings are expected to fall by more than 80% next year as interest costs and empty buildings take their toll.

The quality of cash generation is currently under pressure because Kilroy must spend heavily on building improvements and tenant incentives to fill its empty spaces. Free cash flow turned negative in 2025, hitting minus $120 million, which reveals that the company is spending more on maintaining and developing its properties than it is bringing in from rent.

The balance sheet is managed with a moderate amount of debt, carrying a debt-to-equity ratio of 0.90, which provides some resilience but limits aggressive new spending. Kilroy is sitting on significant assets, but its ability to borrow more is capped by the declining value of office properties and higher market interest rates.

Kilroy is a business in a difficult transition where a high-quality property portfolio is being weighed down by a weak office market and rising development costs.

- Last quarter note: Q4 2025 revenue reached $272.2 million, which slightly missed analyst estimates despite a beat on funds from operations. This result signals a business that is successfully signing new leases but struggling to turn that volume into immediate top-line growth as vacancy remains high.

What's working well? Leasing volume reached a six-year high in the fourth quarter of 2025, showing that there is still demand for premium space at the right price. This surge in activity suggests that while the office market is tough, Kilroy’s specific buildings are still able to win over tenants from lower-quality competitors.

What to watch? Occupancy has fallen to 81.6%, a level that makes it difficult for the company to cover its fixed costs and dividends without depleting its cash reserves. If occupancy does not begin a steady climb back toward 90%, Kilroy may be forced to sell assets at a loss or cut its spending on new projects.

## Moat and competition

- Moat: Narrow
- Industry stage: Mature
- Industry growth estimate: ~2% annually
- Competitors: [Boston Properties. BXP. Large-scale owner of premier East and West Coast office skyscrapers targeting similar tech tenants], [Alexandria Real Estate Equities. ARE. Dominant life science REIT that competes directly for biotech tenants in San Diego and San Francisco], [Hudson Pacific Properties. HPP. West Coast office and studio owner facing similar structural tech-hub occupancy headwinds], [Highwoods Properties. HIW. Office landlord focused on Sun Belt markets which are currently outperforming Kilroy’s coastal regions]
- Moat sources: [Brand & IP. partial], [Cost Advantage. absent], [Switching Costs. partial], [Efficient Scale. absent]
- Moat evidence: [Occupancy: 81.6%], [ROIC: 2.8%], [Revenue Growth: -2.6% YoY]

### Industry
The West Coast office and life science market is a multibillion-dollar industry currently facing its most severe downturn in decades due to the rise of remote work. The traditional office market is a mature industry growing at less than 2% annually, with pricing power shifting heavily toward tenants. While the life science niche remains more resilient, the overall sector is defined by high barriers to entry due to land scarcity and zoning laws. Kilroy stands as a high-end niche player, but its concentration in tech-heavy cities like San Francisco makes it vulnerable to the specific hiring freezes and cost-cutting trends currently hitting that industry.

### Competition
The competitive dynamic for premier office space has become a "flight to quality," where only the newest and best buildings can attract tenants. While the overall market is oversupplied, barriers to building new "trophy" assets are extremely high. This creates a bifurcated market where owners of older buildings are losing everything to owners of modern, sustainable space.

Alexandria Real Estate is the most dangerous threat because it dominates the life science sector that Kilroy is trying to grow into. Boston Properties also competes fiercely for the same large tech tenants in San Francisco and Seattle, often with more diverse geographic footprints that lower their risk. Kilroy is being squeezed by rivals who have either more specialized lab expertise or broader national diversification.

Kilroy is currently losing ground as its occupancy rate remains significantly below its historical levels and its peer group average. The company's 81.6% occupancy rate is a clear signal that it is struggling to defend its market share in a shrinking pool of tenants.

### Moat
Kilroy’s narrow moat comes from its "intangible assets," specifically its portfolio of highly specialized buildings in prime West Coast locations that are nearly impossible to replicate. These properties are designed for the specific needs of tech and biotech firms, creating a form of switching cost because moving an entire lab or a high-tech headquarters is prohibitively expensive. However, this moat only works when there is a line of tenants waiting to get in.

The numbers tell a story of a moat that is failing to protect profits, as the company’s 2.8% ROIC is well below its cost of capital. High-quality assets should produce higher returns, but the current 18.4% vacancy rate suggests that Kilroy’s "trophy" buildings are being treated more like commodities by cost-conscious tenants. The lack of pricing power is visible in the flat revenue and declining earnings.

The forward verdict is that Kilroy’s moat is eroding as the structural shift to remote work permanently reduces the value of even the best office buildings. The single most important signal is the continued struggle to push occupancy back toward 90% without offering massive rent discounts.

## Management

- CEO: Angela Aman
- Management rating: Adequate
- Execution: Mixed
- Execution evidence: FFO beat in Q4 2025 but occupancy remains low at 81.6% after repeated misses.
- Capital allocation: Adequate
- Capital allocation evidence: Sold $755M in assets to fund $192M Torrey Pines life science acquisition.
- Alignment: Mixed
- Alignment evidence: CEO took office in 2024; insider stake is growing but still relatively small.
- Management decision: Acquisition of Nautilus in Torrey Pines for $192M to pivot further into life science
- Management decision: Disposal of $755M in mature or underperforming office assets to strengthen the balance sheet
- Management decision: Continued development of KOP 2 project despite high carry costs and low pre-leasing

Angela Aman is a proven real estate executive who was brought in to lead a difficult turnaround, and her strategy of "capital recycling" shows a disciplined focus on long-term survival. She has successfully sold nearly $800 million of older properties to fund a pivot into life science labs, which is a smarter bet than doubling down on traditional office space. However, her caliber is still being tested by a market that is moving against her, as the company has struggled to fill its vacant buildings fast enough to stop the decline in earnings.

The primary governance risk is that the company’s future depends entirely on management’s ability to execute this high-stakes pivot without a deep bench of life science expertise. While the board is independent, the strategy is a "person-key" bet on Aman’s vision for a smaller, more specialized Kilroy. If she were to leave before the life science projects are finished and leased, the company would be left with a half-completed portfolio and a massive amount of debt in a sector that few other buyers want to touch.

## Quality scorecard

Each business is scored 1 to 5 on what makes a company worth owning for the long term.

- Moat strength: 2 out of 5. Specialized buildings provide some protection, but high vacancy proves the moat is currently failing.
- Capital efficiency: 2 out of 5. ROIC is a low 2.8%, well below the cost of maintaining these expensive coastal properties.
- Revenue growth: 1 out of 5. Revenue is essentially flat as new leases are cancelled out by tenants leaving existing space.
- Growth runway: 3 out of 5. The life science sector offers a multi-billion dollar opportunity, but Kilroy is still a small player.
- Management: 3 out of 5. Angela Aman is making the right strategic sales, but the market is moving faster than her.
- AI resilience: 3 out of 5. AI tech companies still need offices, but they are increasingly efficient with how much space they use.
- Risk resilience: 2 out of 5. The company has struggled to maintain occupancy during this tech downturn, proving its model is sensitive.

## Key numbers (as of July 1, 2026)

- Revenue over the last twelve months: $1.1 billion
- Revenue growth from a year earlier: -2.0%
- Average yearly revenue growth over five years: 3.9%
- Gross margin: 49.9%
- Operating margin: 28.4%
- Free cash flow margin: -3.2%
- Return on invested capital: 2.8%

## Fair value and verdict

Clearthesis also estimates Kilroy Realty's fair value, models what the stock could be worth over the next five years, and gives a verdict (whether it looks like a buy at today's price). Those are on the full thesis: https://www.clearthesis.ai/thesis/KRC?utm_source=ai_agent&utm_medium=markdown

Latest news and what it means for the thesis: https://www.clearthesis.ai/updates/KRC?utm_source=ai_agent&utm_medium=markdown

## Sources

- [SEC 10-K Annual Report](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=KRC&type=10-K&dateb=&owner=include&count=5), July 1, 2026
- [SEC 10-Q Quarterly Report](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=KRC&type=10-Q&dateb=&owner=include&count=5), July 1, 2026
- [krc-20240930](https://www.sec.gov/ix?doc=%2FArchives%2Fedgar%2Fdata%2F1025996%2F000102599624000267%2Fkrc-20240930.htm), July 1, 2026
- [krc-20241231 - SEC.gov](https://www.sec.gov/Archives/edgar/data/1493976/000102599625000052/krc-20241231.htm), July 1, 2026
- [Kilroy Realty - Investor Relations](https://investors.kilroyrealty.com/ir-home/default.aspx), July 1, 2026
- [Press Room - Kilroy Realty - Investor Relations](https://investors.kilroyrealty.com/investors/press-room/default.aspx), July 1, 2026
- [Earnings Press Release (2026-04-30)](https://www.sec.gov/Archives/edgar/data/879101/000119312526193907/kim-ex99_1.htm), April 30, 2026
- [10-K (2025-12-31)](https://www.sec.gov/Archives/edgar/data/879101/000119312526060760/0001193125-26-060760-index.htm), February 20, 2026

Clearthesis research is for information and education only. It is not investment advice.
